Destiny Pharma Share Discussion Threads

[pdt] 25/9/2019 15:23

The interesting point in the video above is that he estimated the phase III will cost about £30m to complete. The large companies are not interested in the antibiotics space and Destiny will struggle fund that sort of amount and if they do there will be massive dilution. And if it is approved will there be any uptake if a very cheap generic does the job just as well? Low margin, low sales and lots of time/funding still to go. I do hold a few but I still need to be convinced.

[aspringo] 16/9/2019 08:58

As mentioned before. Biased and own more than i should but after watching that video, it has confirmed the reason i invested.Never like CEO interviews as i always find them believable and passionate about their companies future, but to me, this feels ok.Good luck to all that have stuck with it.Cheers

[cheshire man] 16/9/2019 08:13

hTTps://youtu.be/JP7OHAWH3A4

[aspringo] 10/9/2019 10:26

I'm biased as own too many, but i just have a feeling that this will end out ok.In the right space at the right time with tech that seems to work.Certainly no share buying advice intended.Fingers crossed for all holders.

[cheshire man] 10/9/2019 10:09

That news bringing in a few buyers and up over 5% I see

[bumpa33] 20/8/2019 10:14

Garraway/CF stock went to WINS, they’ve been moving the stock on since then, I’d guess when they’re finished this will recover, no offer available from any of the other mm’s.

[johnniew156] 15/8/2019 13:22

`The holding on B'berg was held under the name "City Financial". When CF went pop, Garraway took on the fund. The fund was a UK Absolute Return by name but absolute disaster in terms of terrible fund performance and high volatility, so was wound up pdq. So the good news for DEST shareholders is that the recent kicking the stock has just had was/is a) technical and b) over and done with. Up to the company now to prove its worth.

[cottoner] 15/8/2019 11:30

There's my answer. RNS.

[cottoner] 15/8/2019 06:41

A query wrt Garraway's holding. DEST have just under 44m shares in issue. 3% is just over 1.3m shares. I can't see any evidence of Garraway being/having been a major shareholder. Am I missing something?

[gaiusgracchus] 14/8/2019 12:36

Yes agreed johnniew. A further 125k sold this morning so possibly the last of the Garraway stake. No doubt there'll be an RNS to confirm v. soon.

[johnniew156] 14/8/2019 10:24

Literally a couple of minutes after my posting, B'berg popped up with a delayed trade on the QR page. 1.4m shares were crossed at 35p at 15:56.18 yesterday, so yesterday's volume has been adjusted to 1,438,389 shares. In my view it would be extremely coinciental if this sale (of 1.4m shares) was not the balance of the 1.521943m Garraway stake that I am guessing was placed directly into market at least initially & ended up smashing the share price yesterday.

[aspringo] 14/8/2019 10:01

Nice spot, makes sense. Thanks. Providing no upsets from the company themselves, it may be an opportunity, or then again?Good luck with any aim purchase.

[johnniew156] 14/8/2019 09:59

Shareholders should be aware that the Garraway Capital former City of London Fund UK Absolute equity fund managed by David Crawford is being wound up. The fund held 1,521,943 shares of DEST according to Bloomberg as at 30.06.19. Could be coincidence, but a badly managed large sell order would explain the volume surge. hxxps://citywire.co.uk/funds-insider/news/troubled-absolute-return-fund-to-close-four-months-after-suspension/a1254614

[mikeh30] 14/8/2019 08:52

I'm going for a placing

[aspringo] 14/8/2019 07:31

Just my tuppence worth on this share.I'm foolishly topping up and 3 of the purchase made today are mine tjough showing as sales.As far as i can see the story hasnt changed. So far delivered exactly as promised but now the share price is at a fraction of the IPO.Someone may know whats going on, but until then I'll take a chance and keep accumalating.Apologies for my naivety. Good luck all

[gaiusgracchus] 27/5/2019 21:11

Interesting what you say about the length of time this company has taken to get to where it is. I bought some of these after IPO. Not at the top thank goodness but still, I'm down a fair bit. I've subsequently decided to stop investing in biotech stocks. Just don't have the insight required. This doesn't add much to the discussion on Destiny (I'm still holding) but I wish I knew how to figure out if the drug is likely to be successful - in which case we should be piling in - or if it's going to be a dud. I don't know...clearly.

[jack jebb] 16/4/2019 09:23

First bought into this pre IPO over 10 years ago. Its been a long time developing this so called super drug. Would see it 20 bag and a lot more if it did, but after all this time, I have strong doubts.

[edmonda] 16/4/2019 09:15

updated Equity Development research following FY18 results reiterates attractions of their novel antimicrobials pipeline and raises fair value level . Note freely available here: https://www.equitydevelopment.co.uk/edreader/?ltkn=%5bID%5d&d=%3D%3DQO2UjM

[okidokicoki] 28/1/2019 09:42

Bought in here on Friday looks very a interesting company . This drug could revolutionise the antibiotics industry and trails seem to be going well . Sky was pushing this on the IPO so think they will be intrested in it. Never bought on a IPO and have been watching it for over a year . Think this has bottomed and starting to find some traction . GL DYOR

[crowyogapose] 08/1/2019 07:43

Looks like it will be bust soon enough

[superadams] 25/10/2018 21:08

If there is any value here and China Medical bid, try and take paper. They have been a 20 bagger pour moi !

[opodio] 25/10/2018 19:56

15p target

[edmonda] 05/10/2018 10:54

new analysis on pipeline's development and expansion, with increased fair value as a result (a multiple of current share price). Plenty of news expected in coming weeks, too. Note freely accessible here: https://www.equitydevelopment.co.uk/edreader/?ltkn=5f3dec7ebec4cbdaf80bd7d872a074b0AvbosF0F&d=%3D%3DAO4QjM

[mikeh30] 05/9/2018 10:14

https://www.edisoninvestmentresearch.com/research/report/destiny-pharma/preview/?utm_source=edison&utm_medium=EQUISOLVE_press_release&utm_campaign=DEST_04092018